Showing 1,661 - 1,680 results of 140,567 for search '(( 10 ((we decrease) OR (mean decrease)) ) OR ( 50 ((ng decrease) OR (a decrease)) ))', query time: 1.27s Refine Results
  1. 1661
  2. 1662
  3. 1663
  4. 1664
  5. 1665
  6. 1666
  7. 1667

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  8. 1668

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  9. 1669
  10. 1670
  11. 1671
  12. 1672
  13. 1673
  14. 1674
  15. 1675
  16. 1676

    Antibodies used for flow cytometry experiments. by Joseph Rabin (7399436)

    Published 2023
    “…RA was devoid of serious side effects, and within 24 hours from the start of infusion was associated with increased oxygen saturation (93.8 ± 0.58 vs 96.6 ± 1.08%, P<0.05), decreased D-dimer (754 ± 17 vs 518 ± 98 ng/ml, P<0.05), and a trend toward decreased CRP (3.80 ± 1.40 vs 1.98 ± 0.74 mg/dL, P = 0.075). …”
  17. 1677

    Subject flow diagram. by Joseph Rabin (7399436)

    Published 2023
    “…RA was devoid of serious side effects, and within 24 hours from the start of infusion was associated with increased oxygen saturation (93.8 ± 0.58 vs 96.6 ± 1.08%, P<0.05), decreased D-dimer (754 ± 17 vs 518 ± 98 ng/ml, P<0.05), and a trend toward decreased CRP (3.80 ± 1.40 vs 1.98 ± 0.74 mg/dL, P = 0.075). …”
  18. 1678

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
  19. 1679

    Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease by Nguyen Quoc Thai (5348798)

    Published 2018
    “…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
  20. 1680